

Case Report

Fluoxetine, a Selective serotonin reuptake inhibitor overdose resulting in a Central retinal vein occlusion

ABSTRACT:

Aim: We present a rare case of Central retinal vein occlusion after prolonged use of Fluoxetine

Case Presentation : A 28 year old patient presented with clinical picture of Central retinal vein occlusion after prolonged use of Fluoxetine .Discontinuation of the offending drug resulted in resolution of the venous occlusion .

Disussion and Conclusion : Young patientspresenting with central retinal vein occlusions require drug history to be elicited to identify the cause.

KEYWORDS:

Fluoxetine , Selective serotonin reuptake inhibitor ,Central retinal vein occlusion

INTRODUCTION:

Fluoxetine is a selective serotonin reuptake inhibitor which is widely used for the treatment of major depression, obsessive-compulsive disorder(OCD)and panic disorders^{1,2} .Their popular use is due to the acceptable side effect profile as well as low morbidity and mortality³. Following is an unusual complication of the use of fluoxetine in a patient suffering from OCD.

CASE PRESENTATION:

A 28 year old gentleman presented to our clinic with a history of decrease in vision in his right eye since 1 month. There was a history of usage of drug fluoxetine (60 mg daily) since 2 months prescribed by his Psychiatrist. There was no other systemic illness or any other relevant medical history. On examination vision was noted to be 6/6; N6 in both eyes. Ocular movements were full, free, there was no presence of relative afferent pupillary defect. Anterior segment examination was unremarkable; intraocular pressures were noted to be 10mmHg bilaterally. Posterior segment examination of the right eye showed retinal hemorrhages in all quadrants, significant vascular tortuosity and optic disc edema with disc collaterals suggestive of long standing central retinal vein occlusion(CRVO) (figure 1) .The left eye fundus was normal.

Fluorescein angiography demonstrated delayed venous filling suggestive of venous stasis. There was no evidence of any vasculitis. In view of the strong suspicion of CRVO post drug usage the patient was asked to stop the drug and asked for follow up. After stopping the drug there was gradual clearing of the retinal hemorrhages and vascular tortuosity. A 3 months followup showed normal looking retina with complete clearing of the retinal lesions. At final visit the visual acuity was 6/6 with normal intraocular pressures.



Figure 1 : Right Eye fundus photo showing retinal hemorrhages in all quadrants, significant vascular tortuosity and optic disc edema with disc collaterals suggestive of long standing central retinal vein occlusion

DISCUSSION:

Central retinal vein occlusion is the second most common retinal vascular disorder after diabetic retinopathy^{4,5}. Thrombotic occlusions can occur due to a number of pathogenic insults including vessel compression, vessel wall damage, changes in circulatory dynamics and changes in blood composition and clotting⁶.

Selective serotonin reuptake inhibitors(SSRIs) such as Fluoxetine, reduce neural serotonin reuptake; they are also known to modulate peripheral serotonin, including that in platelets⁷. Serotonin has been implicated as a potent potentiator in platelet aggregation. In repeated doses, SSRIs have been found to deplete platelet serotonin stores and have therefore been proposed to reduce the risk of hypercoagulability⁸. However, the initial effect of SSRI treatment is to increase serotonin levels within the target tissues, although the duration of this effect is not known⁹. An increase in platelet serotonin secondary to the use of the SSRI fluoxetine has previously been postulated as an etiological factor in the development of deep venous thrombosis¹⁰. Low mood itself has also been found to increase the risk of thromboembolic stroke through increased platelet activity due to sympatho-adrenal axis hyperactivity.

CONCLUSION:

In our patient we interpret that the use of fluoxetine was a potentiating factor in the platelet aggregation contributing to his central retinal vein occlusion. To the best of the our knowledge this is a rare case of fluoxetine to be reported in the literature to cause a Central retinal vein occlusion. It is an important observation given the popularity of use of SSRIs. Young patients presenting with central retinal vein occlusions require drug history to be elicited to identify the cause.

CONSENT : NOT APPLICABLE

ETHICAL APPROVAL :NOT APPLICABLE

REFERENCES:

1. Sheehan DV. Current concepts in the treatment of panic disorder. *J Clin Psychiatry*. 1999;60 Suppl 18:16-21
2. Gorman JM. The use of newer antidepressants for panic disorder. *J Clin Psychiatry*. 1997;58
3. Cookson J, Duffett R. Fluoxetine: therapeutic and undesirable effects. *Hosp Med*. 1998 Aug;59(8):622-6
4. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. *J Ophthalmol*. 2014
5. Ashraf M, Souka AA, Singh RP. Central retinal vein occlusion: modifying current treatment protocols. *Eye (Lond)*. 2016 Apr;30(4):505-14
- 6- Knox Cartwright NE, Smith P, Tole DM. Branch retinal vein occlusion and fluoxetine. *Ann Ophthalmol* 2007;39(3):253-4
7. Hallbäck I, Hägg S, Eriksson AC, Whiss PA. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. *Pharmacol Rep*. 2012;64(4):979-83
8. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. *Am J Hematol*. 2015 Jun;90
9. Omenn GS, Smith LT. A common uptake system for serotonin and dopamine in human platelets. *J Clin Invest*. 1978 Aug;62(2):235-40
10. Carneiro AM, Blakely RD. Serotonin-, protein kinase C- and 5-HT_{2A}-associated redistribution of the platelet serotonin transporter. *J Biol Chem*. 2006 Aug 25;281(34):24769-80